• Voluntarily signed informed consent and followed the program requirements;

• Females ≥18 and ≤75 years of age at the time of signing the informed consent;

• Expected survival time ≥6 months;

• Patients with HER2-positive invasive breast cancer confirmed by histologic examination;

• Clear hormone receptor (HR) status;

• Clear clinical stage II-III based on American Joint Committee on Cancer (AJCC) staging 8th edition prior to neoadjuvant therapy;

• Primary subjects without antitumor therapy for breast cancer;

• Subjects consenting to mastectomy or breast-conserving surgery at the end of neoadjuvant therapy;

• Radical surgery to the last dose of neoadjuvant therapy at least 2 weeks apart and up to 6 weeks apart;

⁃ Physical status score ECOG 0 or 1;

⁃ Organ function levels must be met provided that blood transfusions are not permitted within 14 days prior to the first administration of study drug, colony-stimulating factors are not permitted, and so on;

⁃ For premenopausal women of childbearing potential a pregnancy test must be performed within 7 days prior to initiation of treatment, serum pregnancy must be negative, and must be non-lactating; all enrolled patients should be using adequate and highly effective contraception throughout the treatment cycle and for 7 months after completion of treatment.